Literature DB >> 20064601

The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps.

Debomoy K Lahiri1, Bryan Maloney.   

Abstract

The neurodegenerative disorder Alzheimer's disease (AD) is the 6th leading cause of death in the USA. In addition to neurological and psychiatric symptoms, AD is characterized by deficiencies in S-adenylmethionine (SAM), vitamin B12, and folate. Deficiency in these nutrients has been shown to result in gene promoter methylation with upregulation of AD-associated genes. While some cases of AD are due to specific mutations in genes such as presenilin 1 (PSEN) and the amyloid-beta peptide precursor protein (APP), these familial AD (FAD) cases account for a minority of cases. The majority of genetic contribution consists of risk factors with incomplete penetrance. Several environmental risk factors, such as cholesterol and diet, head trauma, and reduced levels of exercise, have also been determined for AD. Nevertheless, the majority of risk for AD appears to be established early in life. We propose to explain this via the LEARn (Latent Early-life Associated Regulation) model. LEARn-AD (LAD) would be a "two-hit" disorder, wherein the first hit would occur due to environmental stress within the regulatory sequences of AD-associated genes, maintained by epigenetic changes such as in DNA methylation. This hit would most likely come in early childhood. The second hit could consist of further stress, such as head trauma, poor mid-life diet, or even general changes in expression of genes that occur later in life independent of any pathogenesis. Given that the primary risk for LAD would be maintained by DNA (hypo)methylation, we propose that long-term nutritional remediation based on the LEARn model, or LEARn-based nutritional gain (LEARnING), beginning early in life, would significantly reduce risk for AD late in life. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20064601      PMCID: PMC2881328          DOI: 10.1016/j.exger.2010.01.001

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  56 in total

1.  Gene regulation and DNA damage in the ageing human brain.

Authors:  Tao Lu; Ying Pan; Shyan-Yuan Kao; Cheng Li; Isaac Kohane; Jennifer Chan; Bruce A Yankner
Journal:  Nature       Date:  2004-06-09       Impact factor: 49.962

2.  Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members.

Authors:  R P Friedland; T Fritsch; K A Smyth; E Koss; A J Lerner; C H Chen; G J Petot; S M Debanne
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

3.  Molecular understanding of aluminum-induced topological changes in (CCG)12 triplet repeats: relevance to neurological disorders.

Authors:  Kallur Siddaramaiah Latha; Suram Anitha; Kosagi Sharaf Jagannatha Rao; Mysore Ananthamurthy Viswamitra
Journal:  Biochim Biophys Acta       Date:  2002-10-09

4.  Linguistic ability in early life and the neuropathology of Alzheimer's disease and cerebrovascular disease. Findings from the Nun Study.

Authors:  D A Snowdon; L H Greiner; W R Markesbery
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

5.  Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study.

Authors:  Kathryn P Riley; David A Snowdon; Mark F Desrosiers; William R Markesbery
Journal:  Neurobiol Aging       Date:  2005-03       Impact factor: 4.673

Review 6.  The DNA methyltransferases of mammals.

Authors:  T H Bestor
Journal:  Hum Mol Genet       Date:  2000-10       Impact factor: 6.150

7.  A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease.

Authors:  Paul S Aisen; Susan Egelko; Howard Andrews; Ramon Diaz-Arrastia; Myron Weiner; Charles DeCarli; William Jagust; Joshua W Miller; Ralph Green; Karen Bell; Mary Sano
Journal:  Am J Geriatr Psychiatry       Date:  2003 Mar-Apr       Impact factor: 4.105

8.  Non-familial Alzheimer's disease is mainly due to genetic factors.

Authors:  J Wesson Ashford; James A Mortimer
Journal:  J Alzheimers Dis       Date:  2002-06       Impact factor: 4.472

9.  Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation.

Authors:  Masufumi Takiguchi; William E Achanzar; Wei Qu; Guying Li; Michael P Waalkes
Journal:  Exp Cell Res       Date:  2003-06-10       Impact factor: 3.905

10.  Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1.

Authors:  Michelle A Christensen; Weihui Zhou; Hong Qing; Anna Lehman; Sjaak Philipsen; Weihong Song
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

View more
  52 in total

Review 1.  Beyond the signaling effect role of amyloid-ß42 on the processing of APP, and its clinical implications.

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Exp Neurol       Date:  2010-05-05       Impact factor: 5.330

Review 2.  Folate and Alzheimer: when time matters.

Authors:  Margareta Hinterberger; Peter Fischer
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

Review 3.  Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases.

Authors:  Shivani Ghaisas; Joshua Maher; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2015-11-26       Impact factor: 12.310

4.  Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease.

Authors:  Bryan Maloney; Debomoy K Lahiri
Journal:  Gene       Date:  2012-01-30       Impact factor: 3.688

5.  Brain structural alterations are distributed following functional, anatomic and genetic connectivity.

Authors:  Franco Cauda; Andrea Nani; Jordi Manuello; Enrico Premi; Sara Palermo; Karina Tatu; Sergio Duca; Peter T Fox; Tommaso Costa
Journal:  Brain       Date:  2018-11-01       Impact factor: 13.501

6.  Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis.

Authors:  Jason A Bailey; Bryan Maloney; Yuan-Wen Ge; Debomoy K Lahiri
Journal:  Gene       Date:  2011-06-25       Impact factor: 3.688

7.  Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease.

Authors:  Barbara J Strupp; Brian E Powers; Ramon Velazquez; Jessica A Ash; Christy M Kelley; Melissa J Alldred; Myla Strawderman; Marie A Caudill; Elliott J Mufson; Stephen D Ginsberg
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

8.  Histone deacetylase 2 in the mouse hippocampus: attenuation of age-related increase by caloric restriction.

Authors:  Leonidas Chouliaras; Daniel L A van den Hove; Gunter Kenis; Michael van Draanen; Patrick R Hof; Jim van Os; Harry W M Steinbusch; Christoph Schmitz; Bart P F Rutten
Journal:  Curr Alzheimer Res       Date:  2013-10       Impact factor: 3.498

9.  Gene × environment interaction by a longitudinal epigenome-wide association study (LEWAS) overcomes limitations of genome-wide association study (GWAS).

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Epigenomics       Date:  2012-12       Impact factor: 4.778

10.  How The Genome Got a Life Span.

Authors:  Martine Lappé; Hannah Landecker
Journal:  New Genet Soc       Date:  2015-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.